St John’s University researcher Nitesh Kunda has received a three-year federal grant of $492,000 from the US National Institutes of Health (NIH) for developing an inhalable Covid-19 vaccine.

The vaccine is intended to be inhaled as a dry powder for self-administration by people.

An inhalable vaccine is claimed to elicit potent immune responses in the lungs, which is the initial site of infection, at a reduced dose versus existing vaccines that are given as intramuscular doses.

Kunda serves as an assistant professor at St John’s University Department of Pharmaceutical Sciences Industrial Pharmacy and Pharmaceutics. 

He said: “A major goal of this project is to use the spike protein as an antigen and develop a novel, thermostable, and inhalable Covid-19 vaccine that is easy to scale up, eliminates the need for cold-chain storage and is self-administrable by individuals at home through simple inhalation.”

“In addition, eliminating this cold-chain storage would allow for easy distribution in low-income and middle-income countries with inadequate infrastructure so we can reach remote regions of the world and stockpile vaccines at a lower cost.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The laboratory of the researcher focuses on creating dry powder biologics that do not need cold-chain storage and transport in order to cut down the biologics-based products’ price.

Under this research, a platform technology will be developed for thermostable and inhalable vaccines that address several issues linked to standard vaccines and could be leveraged for developing new vaccines against various infectious diseases.

Earlier this month, the NIH unit National Center For Advancing Translational Sciences (NCATS) awarded $1.1m to Sound Pharmaceuticals (SPI) to develop a new oral Covid-19 treatment, ebselen (SPI-1005).